VolitionRx Limited

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics to revolutionize the diagnosis and monitoring of life-altering diseases. The company's name reflects its founding purpose: "Volition means to have determination and a purpose," a reference to the determination that drives major scientific breakthroughs. Through its subsidiaries, VolitionRx develops and commercializes simple, easy-to-use, cost-effective blood tests designed to help diagnose and monitor a range of diseases, including certain cancers and conditions associated with NETosis such as sepsis. The company's core technology platform is Nu.Q®, a patented nucleosome quantification technology. Nucleosomes and transcription factors are used as biomarkers, and the tests in VolitionRx's portfolio detect characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially better monitoring of disease progression and patient response to treatment. The Nu.Q® platform spans several product pillars, including Nu.Q® Cancer, Nu.Q® Discover, Nu.Q® NETs and Nu.Q® Vet. Nu.Q® NETs is a CE-marked diagnostic solution that clinicians can use to detect NETosis, and the company has announced clinical validation of the Nu.Q® NETs biomarker. Nu.Q® Vet is an affordable veterinary application of the nucleosome quantification technology, currently used for cancer applications in veterinary medicine, with disease areas including canine cancer and feline cancer. In human medicine, VolitionRx is expanding its technology through early clinical trials in cancer, sepsis and beyond, and has presented early Stage I solid cancer detection data at scientific conferences. VolitionRx operates as a multi-national organization with a team of over 70 dedicated staff spanning a wide range of disciplines. Its executive team includes Cameron Reynolds (President & Group Chief Executive Officer), Terig Hughes (Group Chief Financial Officer), Gaetan Michel (Chief Operating Officer), Nick Plummer (Group General Counsel), Louise Batchelor (Group Chief Marketing & Communications Officer), Jake Micallef (Chief Scientific Officer), Gael Forterre (Chief Licensing Officer), Jasmine Kway (Chief Revenue Officer) and Rod Rootsaert (Corporate Secretary). The board is chaired by Timothy I. Still. The company has pursued commercial momentum across multiple pillars, announced collaborations such as one with Sysmex, filed patents protecting its Nu.Q® NETs test, and participated in programs such as the DETECSEPS program launch in France. VolitionRx Limited is publicly traded and reports quarterly financial results.

VolitionRx Limited was founded with the determination to transform lives through earlier disease detection, a purpose reflected in its name: "Volition means to have determination and a purpose." The company was established as a multi-national epigenetic company focused on advancing the science of epigenetics, with operations spanning Belgium, the United States and other markets. The company built its scientific foundation on Nucleosomics™ technology, a patented approach that uses chromosomal structures such as nucleosomes and transcription factors as biomarkers. This technology underpins the Nu.Q® platform, which quantifies nucleosomes to detect characteristic changes occurring from the earliest stages of disease. The Nu.Q® platform has since expanded into multiple product pillars: Nu.Q® Cancer, Nu.Q® Discover, Nu.Q® NETs and Nu.Q® Vet. VolitionRx achieved a significant regulatory milestone with Nu.Q® NETs, a CE-marked diagnostic solution that clinicians can use to detect NETosis, a process associated with conditions such as sepsis. The company has announced clinical validation of the Nu.Q® NETs biomarker and filed new patents protecting the test. In veterinary medicine, Nu.Q® Vet has been commercialized as an affordable application of the nucleosome quantification technology, with disease areas including canine cancer and feline cancer. In human medicine, VolitionRx has pursued early clinical trials in cancer, sepsis and beyond. The company presented early Stage I solid cancer detection data at the ESMO MAP Conference and has demonstrated rapid, point-of-care finger-prick detection. It has also published the first peer-reviewed paper on its Capture-Seq™ technology. VolitionRx has expanded its commercial and collaborative footprint through initiatives such as the DETECSEPS program launch in France and a collaboration with Sysmex. The company has highlighted commercial momentum and multi-pillar expansion across its product portfolio. As a publicly traded company, VolitionRx Limited reports quarterly financial results and has taken steps to strengthen its balance sheet, including the pre-payment in full of a $7.5 million promissory note. Today, VolitionRx operates with a team of over 70 dedicated staff spanning a wide range of disciplines, united in its mission to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection and disease and treatment monitoring.

• VolitionRx established as a multi-national epigenetic company

• Nu.Q® Technology platform developed based on Nucleosomics™ technology

• Nu.Q® NETs receives CE marking as a diagnostic solution for NETosis detection

• Nu.Q® Vet commercialized for veterinary cancer applications

• Clinical validation of Nu.Q® NETs biomarker announced

• Early Stage I solid cancer detection presented at ESMO MAP Conference

• DETECSEPS program launched in France with Volition participation

• Collaboration with Sysmex announced

• New patent filed protecting Nu.Q® NETs test

• First peer-reviewed paper on Capture-Seq™ published

• $7.5 million promissory note pre-paid in full

A multi-national epigenetic company developing simple, easy-to-use, cost-effective blood tests for early detection and monitoring of life-altering diseases.

• Nu.Q® Technology

  Patented nucleosome quantification technology using chromosomal structures such as nucleosomes and transcription factors as biomarkers.

• Nu.Q® Cancer

  Cancer detection and monitoring application of the Nu.Q® platform.

• Nu.Q® Discover

  Discovery application within the Nu.Q® product pillar family.

• Nu.Q® NETs

  CE-marked diagnostic solution for detecting NETosis, associated with conditions such as sepsis.

• Nu.Q® Vet

  Affordable veterinary application of nucleosome quantification technology for canine and feline cancer.

• Capture-Seq™

  Technology with a first peer-reviewed publication.

• Recombinant Nucleosomes

  Product available through the Volition shop.

1. 1Volition - Early Diagnosis and Nucleosome Quantificationvolition.com
2. 2Our Company - Volitionvolition.com
3. 3Our Team - Volitionvolition.com
4. 4Resources - Volitionvolition.com
5. 5VolitionRx (Belgium) - Wikidatawikidata.org